MedTrace Logo

Real-World Observational Study Of Zavicefta to Characterize Use Patterns

NCT03923426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 572

Last updated 2024-06-21

Study results available
· View outcomes & findings →

Summary

This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 12 countries (including but not limited to Austria, France, Germany, Greece, Italy, Spain, United Kingdom, Russia, Argentina, Colombia, Brazil, and Mexico), with possible expansion to other countries as ceftazidime-avibactam is launched. Eligible patients are adults who have been treated with ceftazidime-avibactam in routine practice at participating sites since 01 January, 2018 onwards or since the date of launch in the country if it is posterior to 01 January, 2018. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.

Conditions

Interventions

OTHER

Zavicefta Treatment

Non-interventional - Retrospective Chart Review

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-27
Primary Completion
2022-03-28
Completion
2022-03-28

Countries

  • Argentina
  • Austria
  • Brazil
  • Colombia
  • France
  • Germany
  • Greece
  • Italy
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923426 on ClinicalTrials.gov